Updated Jul 16, 2026
Malabre Richard C is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $69K.

Richard C. Malabre is a corporate figure associated with Akebia Therapeutics, Inc. based on the SEC filing context dated February 4, 2026. The available information from the filing does not clearly specify his exact title or role (e.g., director, officer, or investor) within Akebia or elsewhere. As such, there is no widely published biographical profile available from public sources to confirm his background, career history, or achievements beyond the connection to Akebia in the 2026 filing.
| Role | Insider |
|---|---|
| Notability | 15/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-02-04 | AKBA | Akebia Therapeutics, Inc. | S — Open-market sale [10b5-1] | 13.4K | $1.39 | $19K |
| 2026-02-04 | AKBA | Akebia Therapeutics, Inc. | S — Open-market sale [10b5-1] | 36.1K | $1.39 | $50K |
| 2026-02-03 | AKBA | Akebia Therapeutics, Inc. | A — Grant or award | 79.0K | $0.00 |
Richard C. Malabre is a corporate figure associated with Akebia Therapeutics, Inc. based on the SEC filing context dated February 4, 2026. The available information from the filing does not clearly specify his exact title or role (e.g., director, officer, or investor) within Akebia or elsewhere. As such, there is no widely published biographical profile available from public so…
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($69K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Malabre Richard C profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.